TEST:

OncoSeek®

"SeekIn Inc...today announced that it will present new findings demonstrating the performance and clinical utility of its AI-powered OncoSeek MCED test at the 2025 Early Detection of Cancer Conference in Portland, Oregon."

"SeekIn Inc...Groundbreaking Results Confirm OncoSeek® as a Rapid, Cost-Effective Solution for Global Cancer Early Detection...An international, multi-center clinical trial has validated the effectiveness of OncoSeek®, an advanced AI-powered blood test designed for early detection of multiple cancers. The results, featured in npj Precision Oncology, underscore OncoSeek’s promise in transforming cancer screening, notably in low- and middle-income countries (LMICs). "

Additionally, the symptomatic cohort exhibited a high sensitivity of 73.1% at 90.6% specificity, indicating OncoSeek's potential for cancer early diagnosis. These findings underscore OncoSeek's consistent performances across diverse populations, platforms, and sample types, offering affordable and accessible multi-cancer early detection, especially for LMICs.

"SeekIn Inc...proudly announces that its flagship multi-cancer early detection (MCED) product, OncoSeek®, has been formally recognized in the newly released “Expert Consensus on Liquid Biopsy-Based Multi-Cancer Early Detection (2025 Edition)”. This landmark national expert consensus was jointly issued by China’s top oncology and public health authorities, including the Office of Cancer Screening, National Cancer Center and a multidisciplinary expert panel."

"SeekIn Inc...today announced it has received authorization for five U.S. trademarks, further expanding its robust global intellectual property portfolio. The newly registered trademarks—SeekInCare® (blood-based pan-cancer early detection test), OncoSeek® (blood-based, low-cost multi-cancer early detection test), SeekInClarity® (blood-based pan-cancer treatment response monitoring test), LeukoPrint® (molecular karyotyping test for hematologic malignancies), and PanCanSeek® (precision diagnosis and therapeutic guidance for hematologic malignancies)—mark a significant milestone following successful trademark registrations in China and the European Union."

"SeekIn Inc...announced that it has obtained authorization to use five trademarks within the United States, including SeekInCare® (blood-based pan-cancer early detection test), OncoSeek® (blood-based low-cost multi-cancer early detection test), SeekInClarity® (blood-based pan-cancer treatment response monitoring test), LeukoPrint® (hematologic malignancies molecular karyotyping test), and PanCanSeek® (hematologic malignancies precision diagnosis and therapeutics guidance test). These acquisitions strengthen SeekIn Inc.'s intellectual property portfolio and open new avenues for the company to expand its reach and enhance its services within the United States."

"Biotecgen (Colombia) and OncoInv (The Netherlands) have joined forces to make multi-cancer early detection accessible in Colombia. Biotecgen will offer OncoSeek®, a patient-friendly solution for cancer detection, requiring only a blood sample to detect 9 types of cancer."

"SeekIn Inc...will present cancer early detection technologies at the American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will focus on a lung cancer early detection test and a large-scale clinical validation of multi-cancer early detection test...Lung cancer early detection with LungCanSeek®...Large-scale clinical validation of OncoSeek® multi-cancer early detection test"

"SeekIn Inc...unveiled validation studies of multi-cancer early detection test, breakthrough lung cancer early detection test, and blood-based pan-cancer treatment response monitoring test at EUROMEDLAB 2025...1. Large-scale clinical validation of OncoSeek® multi-cancer early detection test...2. Lung cancer early detection with LungCanSeek®...3 SeekInClarity®: blood-based pan-cancer treatment response monitoring test"

"SeekIn Inc., a leader in blood-based cancer early detection and monitoring technology, unveiled cost-effective Two-Step multi-cancer screening strategy and breakthrough lung cancer early detection test at NKI Early Cancer Detection Conference 2025, ushering in a new era of cancer screening."

"Longevity Medical Institute™ (LMI), Mexico's premier center for regenerative medicine, anti-aging therapies, and advanced diagnostics, announced its collaboration with OncoInv - a global leader in multi-cancer early detection (MCED) with OncoSeek® technology. Together, this collaboration launches one of the most advanced, accessible, and comprehensive cancer screening programs in Latin America, establishing a new standard in proactive, preventive healthcare."

The cost of per cancer case detected was $117,133 for SeekInCare and $172,828 for Galleri, which were 3.5-fold and 5.2-fold higher, respectively, than the two-step MCED ($33,534). The two-step approach not only significantly reduces false positives, but also cuts the screening cost down substantially, making it a cost-effective strategy for population-wide cancer screening.